2023 OAA Fundraising Calendar Ready to Purchase
November 10, 2022
LogicBio® Therapeutics, based in Lexington, Massachusetts, is a clinical-stage genetic medicine company pioneering genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The company's genome editing platform, GeneRide® and gene delivery platform, sAAVy™, are innovative approaches to potentially treat a broad range of indications and tissues.
We’re developing a new form of genome editing based on a technology called GeneRide. It uses a viral vector to carry into the patient’s cells a corrective transgene that’s capable of taking over the duties of the mutated gene causing the patient’s disease. That part is nothing new – it’s a common and well-validated technique used in many gene therapies. What comes next is what makes GeneRide different.
For more information, including about our research in Methylmalonic Acidemia, please visit www.logicbio.com.
